Ligand Pharmaceuticals Q1 2025 Update
Ticker: LGNZZ · Form: 10-Q · Filed: May 9, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Ligand Pharma Q1 2025 filing is out. Check financials.
AI Summary
Ligand Pharmaceuticals Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's filing details its financial performance and operational updates for the period. Specific financial figures and operational highlights are detailed within the report.
Why It Matters
This filing provides investors with a quarterly update on Ligand's financial health and strategic direction, impacting investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Ligand is subject to regulatory, market, and R&D risks inherent in the industry.
Key Numbers
- 2025-03-31 — Reporting Period End (Quarterly financial reporting)
- 2025-05-09 — Filing Date (Date the report was submitted to the SEC)
Key Players & Entities
- LIGAND PHARMACEUTICALS INC (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250509 (date) — Filing Date
- SAN DIEGO (location) — Company Headquarters City
- DE (location) — State of Incorporation
FAQ
What is the reporting period for this 10-Q filing?
The reporting period is the first quarter of 2025, ending on March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 9, 2025.
What is the primary business of Ligand Pharmaceuticals Inc. according to the filing?
Ligand Pharmaceuticals Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where is Ligand Pharmaceuticals Inc. headquartered?
Ligand Pharmaceuticals Inc. is headquartered in San Diego, CA.
What is the fiscal year end for Ligand Pharmaceuticals Inc.?
The fiscal year end for Ligand Pharmaceuticals Inc. is December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding LIGAND PHARMACEUTICALS INC (LGNZZ).